Company
(location)

Product

Description

Indication

Status

Date

AUTOIMMUNE

Anthera Pharmaceuticals Inc. (Hayward, Calif.)

Blisibimod

A selective peptibody antagonist of the B-cell activating factor cytokine

Systemic lupus erythematosus

Failed in a phase III trial; data suggested a positive trend on proteinuria

12/8/16

Catalyst Pharmaceuticals Inc. (Coral Gables, Fla.)

Firdapse

Amifampridine phosphate

Lambert-Eaton myasthenic syndrome

Enrolled the first patient into the second phase III trial

12/16/16

Genentech (unit of Roche Holding AG; Basel, Switzerland)

Ocrevus

Ocrelizumab; a humanized monoclonal antibody designed to selectively target CD20-positive B cells

Relapsing multiple sclerosis

Positive data from three phase III studies – the OPERA I and OPERA II studies and the ORATORIO study – showed consistent and clinically meaningful reductions in major markers of disease activity and progression compared with Rebif (interferon beta-1a, EMD Serono Inc.) in RMS and with placebo in PPMS; the primary endpoint was met in all three studies, which includes relative reduction of annualized relapse rate in the RMS studies and relative reduction in the progression of clinical disability sustained for at least 12 weeks in the PPMS study

12/23/16

Redhill Biopharma Ltd. (Tel Aviv, Israel)

RHB-104

Targets a specific pathogen

Crohn's disease

Received a unanimous recommendation from the independent data and safety monitoring board to continue without any modification its ongoing phase III study

12/14/16

UCB SA (Brussels) and Dermira Inc. (Menlo Park, Calif.)

Cimzia

Certolizumab pegol

Moderate-to-severe chronic plaque psoriasis

Top-line results from CIMPASI-1, a placebo-controlled phase III trial, demonstrated statistically significant improvements for both co-primary endpoints compared to placebo at both treatment doses

12/9/16

Valeant Pharmaceuticals International Inc. (Laval, Quebec)

IDP-118

Halobetasol propionate and tazarotene lotion

Plaque psoriasis

A multicenter, double-blind, randomized, vehicle-controlled phase III study showed statistical significance, with a treatment success rate of 45.33% (p<0.001) compared to vehicle

12/9/16

CANCER

Astrazeneca plc (London)

Tagrisso

Osimertinib

EGFR T790M mutation-positive locally-advanced or metastatic non-small-cell lung cancer

Data from the AURA3 trial showed that Tagrisso second-line therapy improved progression-free survival (PFS) by 5.7 months compared with standard platinum-based doublet chemotherapy

12/7/16

Astrazeneca plc (London)

Tagrisso

EGFR inhibitor; osimertinib

Lung cancer

AURA3 phase III trial showed Tagrisso second-line therapy improved progression-free survival (PFS) by 5.7 months compared with standard platinum-based doublet chemotherapy (HR=0.3)

12/12/16

Celgene Corp. (Summit, N.J.)

Abraxane

Paclitaxel protein-bound particles for injectable suspension

Non-small-cell lung cancer

Interim results from the ABOUND clinical trial program evaluating the use of Abraxane found that 91 (73%) patients experienced grade ≥2 peripheral neuropathy (PN) or grade ≥3 myelosuppression; the median overall survival was 14.6 months and the median progression-free survival was 6.2 months

12/7/16

Celgene Corp. (Summit, N.J.)and Takeda Oncology Co. (Cambridge, Mass.)

VRd

Revlimid (lenalidomide) and Velcade (bortezomib) and dexamethasone

Myeloma

Phase III data showed that a three-drug combination delays recurrence and lengthens life; one regimen used Revlimid and dexamethasone; the other regimen also included Velcade; the addition of Velcade earlier gave patients about another year of remission and another year of life compared to the standard two-drug regimen; patients receiving all three in their first six months of treatment had a median remission time of 43 months compared to a median remission of 30 months for patients who received lenalidomide and dexamethasone alone

12/27/16

Cel-Sci Corp. (Vienna, Va.)

Multikine

Leukocyte interleukin, injection

Squamous cell carcinoma of the head and neck

FDA issued an incomplete response to the hold letter; the company said it is reviewing all of its options and plans to send the FDA a request to discuss all matters relating to the partial clinical hold

12/27/16

Celsion Corp. (Lawrenceville, N.J.)

Thermodox

Heat-activated liposomal encapsulation of doxorubicin

Primary liver cancer

The study's data monitoring committee unanimously recommended that the phase III trial continue enrollment; about 40% of patients are currently enrolled in the trial

12/1/16

Celsion Corp. (Lawrenceville, N.J.)

Thermodox

Heat-activated liposomal encapsulation of doxorubicin

Primary liver cancer

Met with CFDA officials to discuss the ongoing phase III OPTIMA program and regulatory pathway, and presented a survival benefit in patients treated with Thermodox plus optimized radiofrequency ablation (RFA) compared with optimized RFA alone; the CFDA agreed that OPTIMA, if successful, could serve as the basis for a direct regulatory filing in China without the need to file for prior approval in the U.S. or EU.

12/19/16

Mylan NV (Hertfordshire, U.K.) and Biocon Ltd. (Bangalore, India)

MYL-1401O

Proposed biosimilar trastuzumab (Herceptin, Roche Holding AG)

HER2-positive breast and gastric cancers

Results of the HERITAGE study confirm the efficacy, safety and immunogenicity of MYL-1401O in comparison to branded trastuzumab

12/28/16

Northwest Biotherapeutics Inc. (Bethesda, Md.)

Dcvax-L

N/A

Glioblastoma multiforme

331 of the planned 348 patients were enrolled in its phase III trial, with data events accumulating toward the trial endpoints; the trial has been under a partial clinical hold on recruitment that has not been lifted by regulators, and the company said it will no longer seek to enroll the final 17 patients

12/9/16

Novartis AG (Basel, Switzerland)

Zykadia

Ceritinib; first-line ALK inhibitor

Anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Results from its phase III open-label, randomized, active-controlled, multi-center ASCEND-4 study found that patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months compared to 8.1 months in patients treated with standard first-line chemotherapy with maintenance

12/7/16

Novartis AG (Basel, Switzerland)

LEE011

Ribociclib

Hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer

Phase III MONALEESA-2 data show LEE011 plus letrozole significantly prolonged progression-free survival (PFS) across pre-planned patient subgroups

12/12/16

Novartis AG (Basel, Switzerland)

LEE011 and Femara

Cyclin-dependent kinase 4/6 pathway inhibitor in combination with letrozole

HR-positive/HER2-negative locally advanced breast cancer

The MONALEESA-2 pivotal trial of ribociclib in combination with letrozole vs. letrozole alone in postmenopausal women who had received no prior therapy showed the combination treatment significantly improved progression-free survival

12/28/16

Pfizer Inc. (New York)

PF-05280014

Biosimilar to Herceptin

HER2-positive metastatic breast cancer

The pivotal REFLECTIONS B3271002 study, of PF-05280014 vs. Herceptin (trastuzumab, Roche Holding AG), met its primary endpoint, demonstrating equivalence in the primary endpoint of objective response rate when taken in combination with paclitaxel

12/1/16

Pfizer Inc. (New York)

Palbociclib

Cyclin-dependent kinase inhibitor Ibrance

Estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

Positive results from a sub-analysis studying Asian patients in the phase III PALOMA-2 trial of Ibrance, in combination with letrozole, as first-line therapy extended progression-free survival (PFS) by more than 11 months compared to letrozole plus placebo, and demonstrated that the median PFS exceeded two years

12/22/16

Pfizer Inc. (New York)

Ibrance

Palbociclib

Estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

A subanalysis from the Paloma-2 trial studying Asian postmenopausal women showed that when treated with Ibrance and letrozole it significantly extended progression-free survival by more than 11 months compared with letrozole plus placebo; PFS exceeded two years in those patients, a benefit consistent with Ibrance in the overall global population.

12/23/16

Pfizer Inc. (New York) and Avillion LLP (London)

Bosulif

Bosutinib

Chronic phase Philadelphia chromosome positive chronic myeloid leukemia

Results from the phase III BFORE trial demonstrated superiority of Bosulif over imatinib (Gleevec, Novartis AG) as a first-line treatment; the study met its primary endpoint of major molecular response (MMR) at 12 months

12/6/16

Progenics Pharmaceuticals Inc. (New York)

99mTc-MIP-1404

PSMA-targeted SPECT/CT imaging agent candidate

Newly diagnosed or low-grade prostate cancer

The independent data monitoring committee completed review of an interim analysis of the phase III trial, and recommended that the trial continue

12/27/16

Sandoz (unit of Novartis AG; Basel, Switzerland)

GP2013

Biosimilar of Mabthera (rituximab, Roche AG), a monoclonal antibody that targets CD20

Advanced follicular lymphoma

The ASSIST-FL trial shows GP2013 met its primary endpoint of overall response rate (87.1%), demonstrating equivalence with the reference product, Mabthera, in 629 patients

12/6/16

Sanofi Genzyme (unit of Sanofi SA; Cambridge, Mass.)

Isatuximab

Anti-CD38 monoclonal antibody

Relapsed and refractory multiple myeloma

Initiated the ICARIA-MM phase III trial

12/6/16

TG Therapeutics Inc. (New York)

TG-1101

Glycoengineered anti-CD20 monoclonal antibody

High-risk relapsed or refractory chronic lymphocytic leukemia

The target enrollment of 120 patients in the GENUINE phase III study has been met and enrollment will be closed shortly

12/7/16

VBL Therapeutics Inc. (Tel Aviv, Israel)

VB-111

Ofranergene obadenovec

Recurrent glioblastoma

The independent data safety monitoring committee (DSMC) met to conduct its first safety review of the phase III GLOBE Study and did not find any adverse events that would be cause for concern

12/6/16

Xbiotech Inc. (Austin, Texas)

Xilonix

IgG1k monoclonal antibody immunotherapy

Advanced colorectal cancer

Enrollment has been completed in its randomized, double-blind, placebo-controlled phase III study

12/8/16

CARDIOVASCULAR

Akcea Therapeutics Inc.

Volanesorsen

Designed to reduce apolipoprotein C-III (apoC-III) production and lower triglycerides

Cardiometabolic lipid disorders

COMPASS, the first phase III study, met its primary endpoint, with patients who received the drug (n=75) achieving a statistically significant (p<0.0001) mean reduction in triglycerides of 71.2% from baseline following 13 weeks of treatment compared with a mean reduction of 0.9% in placebo-treated patients (n=38)

12/20/16

Biocardia Inc. (San Carlos, Calif.)

CardiAMP

Autologous, minimally processed bone marrow cell therapy

Heart failure

Initiated a randomized, controlled pivotal trial

12/30/16

Cytokinetics Inc. (South San Francisco)

Omecamtiv mecarbil

A cardiac myosin activator

Heart failure

Started the GALACTIC-HF phase III cardiovascular outcomes trial

12/2/16

Eagle Pharmaceuticals Inc. (Woodcliff Lake, N.J.)

Ryanodex

Dantrolene sodium

Exertional heat stroke

In its pivotal animal study conducted under the Animal Rule, for Ryanodex, significantly more animals treated with Ryanodex in addition to the standard of care (SOC) achieved the primary efficacy endpoint, which was reversal of the induced heat stroke/hypermetabolic crisis, compared to animals treated with SOC alone

12/14/16

Genentech (unit of Roche Holding AG; Basel, Switzerland)

ACE910

Emicizumab; bispecific monoclonal antibody

Hemophilia A

Top-line data from the phase III HAVEN1 study showed a statistically significant reduction in the number of bleeds over time for emicizumab patients vs. those with no prophylactic treatment; the study also met all secondary endpoints, including a statistically significant reduction in the number of bleeds with emicizumab in an intra-patient comparison that brought aboard people who had received prior bypassing-agent prophylaxis

12/23/16

Shire plc (Dublin)

Vonvendi

Von Willebrand factor (recombinant)

Severe von Willebrand disease

Top-line results from a phase III trial of Vonvendi to treat bleeds in elective surgical settings for adults with severe von Willebrand disease showed it met its primary endpoint, finding that overall hemostatic efficacy was "excellent" or "good" for the 15 treated subjects

12/5/16

Vifor Pharma Ltd.

Ferinject

Ferric carboxymaltose

Chronic heart failure and iron deficiency

An open label study found a "significantly beneficial effect" for Ferinject on exercise capacity, confirming the findings of previous studies

12/8/16

CENTRAL NERVOUS SYSTEM

Alzheon Inc. (Framingham, Mass.)

Tramiprosate

Amyloid anti-aggregation agent and the active molecule

APOE4/4 homozygous Alzheimer's disease

Additional analyses of phase III data showed tramiprosate's largest efficacy signals occurred on cognition and function in individuals who carry two e4 alleles of apolipoprotein E gene (APOE4/4 homozygotes) and are diagnosed with mild AD, defined as MMSE of 22 and higher

12/12/16

Flamel Technologies SA (Lyon, France)

FT218

A once-nightly formulation

Excessive daytime sleepiness and cataplexy in narcolepsy

The first patient was dosed in its Rest-On phase III trial

12/19/16

Otsuka Pharmaceutical Development & Commercialization Inc. (part of Otsuka Pharmaceuticals Co. Ltd.; Tokyo) and H. Lundbeck A/S (Valby, Denmark)

Abilify Maintena

An extended-release injectable formulation of aripiprazole

Bipolar I disorder

Phase III data showed it significantly delayed time to recurrence of any mood episode during a 52-week treatment study compared with placebo (p<0.0001)

12/8/16

Pfizer Inc. (New York)

Lyrica

Pregabalin capsules CV and oral solution CV

Pediatric epilepsy

Top-line results showed that adjunctive treatment with Lyrica 10 mg/kg/day resulted in a statistically significant reduction in seizure frequency vs. placebo

12/2/16

Pharnext SA (Paris)

PXT3003

Pleodrug

Charcot-Marie-Tooth disease type 1A

Completed patient enrollment in its pivotal, phase III PLEO-CMT trial

12/21/16

Scilex Pharmaceuticals Inc. (San Diego)

Ztlido

Lidocaine patch 1.8%

Post-herpetic neuralgia

Pivotal study for Ztlido met a primary endpoint establishing comparative pharmacokinetics and a secondary endpoint of bioequivalence for Ztlido as compared to the reference product, Lidoderm (lidocaine patch 5%, Endo Pharmaceuticals Inc.)

12/6/16

TherapeuticsMD Inc. (Boca Raton, Fla.)

TX-001HR

A bio-identical hormone therapy combination 17ß-estradiol and progesterone in a single, oral softgel

Moderate to severe vasomotor symptoms due to menopause

Pivotal phase III data showed that TX-001HR estradiol 1 mg/progesterone 100 mg and TX-001HR estradiol 0.5 mg/progesterone 100 mg both achieved all four of the co-primary efficacy endpoints and the primary safety endpoint; they both demonstrated a statistically significant and clinically meaningful reduction from baseline in both the frequency and severity of hot flashes

12/7/16

DIABETES

Novo Nordisk A/S (Bagsvaerd, Denmark)

Xultophy

Once-daily single injection fixed combination of long-acting insulin degludec

Type 2 diabetes

Phase IIIb trial in combination with insulin aspart at all main meals, showed that after 26 weeks, the trial successfully demonstrated it is non-inferior to insulin glargine U100 in combination with insulin aspart with regards to lowering of HbA1c; from a mean baseline HbA1c of 8.2%, both patient groups reached a similar HbA1c level of 6.7% after 26 weeks of treatment

12/5/16

GASTROINTESTINAL

Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) and Allergan plc (Dublin)

Linzess

A peptide agonist of guanylate cyclase 2C

Irritable bowel syndrome with constipation

Disclosed positive top-line data from a phase IIb trial that showed numerically greater abdominal pain improvement with 300 mcg compared to placebo and to the 290 mcg immediate-release (IR) formulation of linaclotide

12/23/16

Synergy Pharmaceuticals Inc. (New York)

Plecanatide

A guanylate cyclase C receptor agonist

Irritable bowel syndrome with constipation

Phase III trials showed that plecanatide 3 mg and 6 mg, administered orally once daily, met the primary endpoint and showed statistical significance in the percentage of overall responders compared to placebo during 12 weeks of treatment; the second pivotal trial indicated that both doses met the primary endpoint and showed statistical significance in the percentage of overall responders

12/12/16

INFECTION

Achaogen Inc. (South San Francisco)

Plazomicin

A next-generation aminoglycoside antibacterial derived from sisomicin

Complicated urinary tract infections and acute pyelonephritis

Phase III EPIC showed non-inferiority compared to meropenem, and superiority in the EMA's primary efficacy endpoints of microbiological eradication at the test-of-cure visit

12/13/16

Cempra Inc. (Chapel Hill, N.C.) and Toyama Chemical Co. Ltd. (Tokyo)

Solithromycin

A ketolide antibiotic

Community-acquired bacterial pneumonia and other respiratory infections

Has begun phase III clinical trials

12/6/16

Cytodyn Inc. (Vancouver, Wash.)

PRO 140

Fully humanized monoclonal antibody targeting the CCR5 entry receptor

HIV

The first patients were treated in its phase III trial with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects

12/13/16

Janssen Sciences Ireland UC (Cork, Ireland) and Viiv Healthcare Ltd. (Brentford, U.K)

Rilpivirine and dolutegravir

Antiretrovirals

HIV

Two phase III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four drug antiretroviral regimen to the two drug regimen of rilpivirine (Janssen) and dolutegravir (Viiv Healthcare) met the primary endpoint of noninferiority at week 48

12/21/16

Merck & Co. Inc. (New York)

VSV-ZEBOV

Vaccine

Ebola

Final results of the phase III ring vaccination study show it to be 100% effective, with no one who received the vaccine contracting the virus

12/27/16

Nabriva Therapeutics AG (Vienna)

Lefamulin

A semisynthetic pleuromutilin antibiotic

Moderate to severe community-acquired bacterial pneumonia

Achieved 60% of its enrollment target in the lefamulin evaluation against pneumonia (LEAP) 1 trial; LEAP 1 is a global, registrational, phase III trial

12/21/16

Paratek Pharmaceuticals Inc. (Boston)

Omadacycline

An aminomethylcycline

Community-acquired bacterial pneumonia

Projects its ongoing pivotal phase III study will report top-line data during the second quarter of 2017, compared to the earlier estimate for data as early as the third quarter of 2017, due to faster-than-expected enrollment

12/14/16

MISCELLANEOUS

Aerie Pharmaceuticals Inc. (Irvine, Calif.)

Roclatan

Netarsudil/latanoprost ophthalmic solution

Glaucoma or intraocular pressure

Completed patient enrollment in the company's second phase III registration trial (Mercury 2)

12/8/16

Aytu Bioscience Inc. (Englewood, Colo.)

Natesto

Nasal testosterone gel

Hypogonadism

Demonstrated significant clinical improvements in erectile function and mood in hypogonadal men in the multicenter phase III

12/1/16

Azurrx Biopharma Inc. (Brooklyn, N.Y.) and Mayoly Spindler SAS (Chatou Cedex, France)

MS1819-SD

A recombinant enzyme that is derived from the yarrowia lipolytica lipase

Exocrine pancreatic insufficiency

Enrolled the first three patients in a phase IIa trial

12/22/16

Biomarin Pharmaceutical Inc. (San Rafael, Calif.)

Vosoritide

Analog of C-type natriuretic peptide

Achondroplasia, the most common form of dwarfism

Initiated a global phase III study in children

12/13/16

Biotime Inc. (Alameda, Calif.)

Renevia

Injectable matrix; designed to mimic the extracellular matrix and provide a 3-D scaffold

For whole adipose tissue fat transfer procedures

Has enrolled more than 50 patients in its pivotal trial

12/15/16

Bluebird Bio Inc. (Cambridge, Mass.)

Lentiglobin

Gene therapy

Transfusion-dependent beta-thalassemia and non-beta0/beta0 genotypes

Treated the first patient in Northstart-2, a phase III trial

12/15/16

Galena Biopharma Inc. (San Ramon, Calif.)

GALE-401

Anagrelide controlled release

Essential thrombocythemia

Confirmed the regulatory pathway to advance GALE-401 into a pivotal phase III trial following a meeting with the FDA

12/29/16

GW Pharmaceuticals plc (London)

Epidiolex

A formulation of cannabidiol, an anti-convulsant

Dravet syndrome and Lennox-Gastaut syndrome

Disclosed additional positive Epidiolex phase III data that reinforce the robust nature of the results achieved in two of the most difficult-to-treat epilepsy patient populations

12/6/16

Horizon Pharma plc (Dublin)

Actimmune

Interferon gamma-1b

Friedreich's ataxia

Failed in a phase III trial, STEADFAST, which missed its primary and secondary endpoints; company is winding down the program

12/9/16

Ophthotech Corp. (New York)

Fovista

Pegpleranib; anti-platelet-derived growth factor therapy

Wet age-related macular degeneration

The pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase III trials

12/13/16

Proteon Therapeutics Inc. (Waltham, Mass.)

Vonapanitase

Recombinant human elastase

Chronic kidney disease

Phase III PATENCY-1 trial missed its primary endpoint of improved primary unassisted patency compared to placebo; top-line data for the trial's secondary endpoint showed it may improve secondary patency compared to placebo, however, and data from one of three tertiary endpoints suggested the drug may improve fistula use in hemodialysis

12/14/16

Revance Therapeutics Inc. (Newark, Calif.)

RT002

Daxibotulinum-toxinA

Moderate to severe frown lines

Started dosing patients enrolled in the company's phase III study of daxibotulinumtoxinA for the treatment of moderate to severe frown lines in adults

12/8/16

Strongbridge Biopharma plc (Trevose, Pa.)

COR-003

Levoketoconazole; a cortisol synthesis inhibitor

Endogenous Cushing's syndrome

Plans to initiate a second phase III study, LOGICS, which will supplement the long-term efficacy and safety data from the ongoing SONICS study; LOGICS enrollment is anticipated to begin midyear 2017 and top-line data are expected in the third quarter of 2018

12/27/16

RESPIRATORY

Anthera Pharmaceuticals Inc. (Hayward, Calif.)

Sollpura

Liprotamase; recombinant pancreatic enzyme replacement therapy

Cystic fibrosis patients with exocrine pancreatic insufficiency

Topline phase III SOLUTION clinical study data showed it narrowly missed the coefficient of fat absorption (CFA) non-inferiority margin of the primary modified intent-to-treat analysis; however, by additional pre-specified analyses of CFA, Sollpura met the non-inferiority criterion; the study also confirmed that the ratio of the three enzymes in Sollpura demonstrated an appropriate response in the coefficient of nitrogen absorption

12/29/16

Aradigm Corp. (Hayward, Calif.)

Pulmaquin

Formulation of once-daily ciprofloxacin for inhalation

Non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa

Top-line results showed that the median time to first mild, moderate or severe pulmonary exacerbation was 230 days in the Pulmaquin group, compared to 163 days in the placebo group (p=0.0462), showing statistical significance in the ORBIT-4 trial; it was 221 days for Pulmaquin and 136 days for placebo in the ORBIT-3 trial, which missed statistical significance (p=0.8488)

12/2/16

Glaxosmithkline plc (London) and Innoviva Inc. (Brisbane, Calif.)

Fluticasone furoate/umeclidinium/vilanterol

Inhaled corticosteroid (ICS); long-acting muscarinic antagonist; long-acting beta2-adrenergic agonist

Asthma

Started a phase III study investigating the effects when compared to therapy with Relvar/Breo

12/20/16

Lexicon Pharmaceuticals Inc. (The Woodlands, Texas)

Sotagliflozin

First-in-class, oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2

Type 1 diabetes

The pivotal inTandem1 phase III clinical trial met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin; top-line results showed that patients treated with sotagliflozin had a mean A1C reduction from baseline of 0.43% on 200mg once daily sotagliflozin dose (p<0.001) and a reduction of 0.49% on 400mg once daily sotagliflozin dose (p<0.001) as compared to a reduction of 0.08% on placebo after 24 weeks of treatment

12/22/16

Notes

Public biopharmaceutical company stock symbols can be found in the stock report located on the last two pages of this issue.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

For more information about individual companies and/or products, see Thomson Reuters Cortellis.